Drug Trial Radar · NCT06438172
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
249
Actual
Start
Mar 25, 2024
Primary completion
Dec 2, 2024
Study completion Dec 2, 2024
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension
Conditions
- Hypertension
Interventions
HCP1803-3Drug
Take it once daily for 8 weeks orally.
RLD2001-1Drug
Take it once daily for 8 weeks orally.
HPP2003-3Drug
Placebo drug. Take it once daily for 8 weeks orally.
HPP2002-1Drug
Placebo drug. Take it once daily for 8 weeks orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in sitting systolic blood pressureTime frame: baseline, 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Donggguk University Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.